R402
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 6
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- WNT_BETA_CATENIN_SIGNALING+0.460
- INTERFERON_ALPHA_RESPONSE+0.380
- KRAS_SIGNALING_DN+0.360
- KRAS_SIGNALING_UP+0.340
- PANCREAS_BETA_CELLS+0.320
- G2M_CHECKPOINT+0.290
- ANGIOGENESIS+0.260
- HEDGEHOG_SIGNALING+0.260
- E2F_TARGETS+0.250
Top 10 suppressed
- PROTEIN_SECRETION-0.460
- OXIDATIVE_PHOSPHORYLATION-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.390
- ADIPOGENESIS-0.370
- MYC_TARGETS_V2-0.360
- DNA_REPAIR-0.300
- PI3K_AKT_MTOR_SIGNALING-0.290
- PEROXISOME-0.260
- MTORC1_SIGNALING-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R396 | — | — | 0.818 |
| 2 | TCGA-56-A4BW-01A-11R-A24H-07 | — | cohortSQ1 | 0.813 |
| 3 | MNG29 | — | — | 0.795 |
| 4 | BS_97M1E2DW | Diffuse intrinsic pontine glioma | — | 0.795 |
| 5 | GSM5359446 | — | — | 0.788 |
| 6 | MNG55 | — | — | 0.773 |
| 7 | R14 | — | — | 0.762 |
| 8 | SRR1321674 | GTEX | — | 0.753 |
| 9 | 20030032.TNBC | — | D | 0.752 |
| 10 | TCGA-66-2790-01A-01R-0980-07 | — | cohortSQ1 | 0.747 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.460 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.360 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.340 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.190 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.080 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |